Insider Buying: Sienna Biopharm (SNNA) Director Acquires 16,700 Shares of Stock

Sienna Biopharm (NASDAQ:SNNA) Director Keith R. Leonard bought 16,700 shares of the company’s stock in a transaction on Tuesday, August 1st. The stock was purchased at an average price of $15.00 per share, with a total value of $250,500.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Sienna Biopharm (NASDAQ SNNA) traded up 1.73% during trading on Friday, reaching $19.38. The company’s stock had a trading volume of 76,768 shares. Sienna Biopharm has a 52-week low of $18.50 and a 52-week high of $21.20.

TRADEMARK VIOLATION WARNING: This news story was originally posted by Rincon Hill News and is the property of of Rincon Hill News. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://rinconhillneighbors.org/2017/08/19/sienna-biopharmaceuticals-inc-snna-director-keith-r-leonard-acquires-16700-shares-updated-updated.html.

Sienna Biopharm Company Profile

Sienna Biopharmaceuticals, Inc is a United States-based medical dermatology and aesthetics company. The Company focuses on developing targeted therapies to treat inflammatory skin conditions and aesthetic concerns that impact the health and appearance of patients. Its research and clinical-stage candidates include programs, such as SNA-001, SNA-120 and SNA-125.

Receive News & Ratings for Sienna Biopharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharm and related companies with our FREE daily email newsletter.

 

Latest News



Leave a Reply

 
© 2006-2017 Rincon Hill News.